Actively Recruiting
Study of CGT6297, a Mutant-Selective Inhibitor, in Adults With Advanced Solid Tumors Having PIK3CA Mutations
Led by Cogent Biosciences, Inc. · Updated on 2026-10-22
90
Participants Needed
12
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating CGT6297, a mutant-selective inhibitor, in adults with advanced solid tumors that have PIK3CA mutations. This Phase 1, open-label, nonrandomized study aims to understand the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of CGT6297. The study targets patients whose tumors include endometrial cancer, HR-positiveHER2-negative breast cancer, HER2-low breast cancer, and other solid tumors with PIK3CA mutations. The study has two parts Phase 1a focuses on dose escalation of multiple oral doses of CGT6297 to identify appropriate dosing, while Phase 1b involves treating participants at the selected dose level to further assess effects. Participants receive CGT6297 by daily oral administration. The study is designed sequentially to first determine safe and tolerable doses and then to explore the drugs activity in different tumor types. Participants will be monitored through clinical and laboratory assessments, including blood tests, imaging scans to measure tumor lesions, and evaluations of heart function. Researchers will track adverse events, serious adverse events, and overall tumor response. The study includes safety monitoring over approximately 12 months in Phase 1a and about 8 months in Phase 1b. Participants involvement includes regular visits for dosing and assessments throughout these periods.
CONDITIONS
Brief Title
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Research Team
C
Cogent Biosciences, Inc
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here